Synopsis The prevalence of MDR HIV-1 infection has declined over the years, yet those infected with these strains are vulnerable to treatment failure and worsened clinical outcomes. Such patients require the use of new antiretroviral agents with a good safety and side-effect profile, without drug interactions or cross-resistance. The present study evaluates the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1. This week’s “ MED FACT ” discusses a randomized, multicenter, Phase 3 trial from The New England Journal of Medicine, “ Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 ”. Authors: B.
Emu, et. al. Key Takeaways Ibalizumab had significant antiviral activity in patients with MDR HIV-1 infection who had advanced disease and limited treatment options, during the 25-week study. Objective: The present study…
